DexCom, Inc.

NasdaqGS:DXCM

Sector

🏥 Health Care

Industries

💻 Telehealth

🔬 Clinical Trials

🌐 Internet of Things (IoT)

🩺 Medical Instruments

Location

United States

Market Cap

USD 33.20 B

Share Price

USD 84.68

Avg Daily Volume

4,247,603

Change (1 day)

-3.30%

Change (1 year)

-23.23%

Change (YTD)

8.88%

DexCom, Inc. Short-Term Debt for the year ending December 31, 2024: USD 1.23 B

DexCom, Inc. Short-Term Debt is USD 1.23 B for the year ending December 31, 2024, a 5,714.69% change year over year. Short-term debt are debt obligations that are due within one year.

DexCom, Inc. Short-Term Debt for the year ending December 31, 2023 was USD 21.10 M, a -97.34% change year over year.
DexCom, Inc. Short-Term Debt for the year ending December 31, 2022 was USD 793.10 M, a 1,834.39% change year over year.
DexCom, Inc. Short-Term Debt for the year ending December 31, 2021 was USD 41.00 M, a 24.24% change year over year.
DexCom, Inc. Short-Term Debt for the year ending December 31, 2020 was USD 33.00 M, a 21.32% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Short-Term Debt	Long-Term Debt	Total Liabilities	Shareholders' Equity

NasdaqGS: DXCM

DexCom, Inc.

CEO	Mr. Kevin Ronald Sayer
IPO Date	April 14, 2005
Location	United States
Headquarters	6340 Sequence Drive
Employees	10,200
Sector	🏥 Health Care
Industries Telehealth 🔬 Clinical Trials 🌐 Internet of Things (IoT) 🩺 Medical Instruments

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.